scholarly journals Impact of the black triangle label on prescribing of new drugs in the United Kingdom: lessons for the United States at a time of deregulation

2017 ◽  
Vol 26 (11) ◽  
pp. 1307-1313 ◽  
Author(s):  
Daniel B. Horton ◽  
Tobias Gerhard ◽  
Amy Davidow ◽  
Brian L. Strom
Keyword(s):  
United States ◽  
United Kingdom ◽  
The United States ◽  
New Drugs ◽  
Black Triangle ◽  
The United Kingdom

The Drug Lag Issue: The Debate Seen from an International Perspective

1992 ◽  
Vol 22 (1) ◽  
pp. 53-72 ◽  
Author(s):  
Fredrik Andersson
Keyword(s):  
United States ◽  
United Kingdom ◽  
Processing Time ◽  
The United States ◽  
International Perspective ◽  
West Germany ◽  
New Drugs ◽  
Regulatory Agencies ◽  
The United Kingdom ◽  
Drug Lag

This article reviews the literature related to the “drug lag” issue, i.e., the issue of whether important new drugs are introduced relatively late, or, in certain cases, are introduced at all, in a particular country. The literature can be divided into two main parts: studies primarily related to the delay in introduction of new drugs and studies primarily related to the number of introduced new drugs. Most studies have found the United States, Sweden, and Norway to have a long delay in the introduction of new drugs. The United Kingdom and (West) Germany in general have the shortest delay. There are also large differences in the number of introduced new drugs. In most studies, the United States and Norway have introduced far fewer new drugs than any other industrialized country. In general (West) Germany, France, the United Kingdom, and Italy have introduced the largest number of new drugs. One of the reviewed studies presented a relationship between regulatory processing time and delay in introduction. Another study found an increasing influence of regulatory stringency on the number of introduced new drugs in a country. If a country's aim is to decrease the delay in introduction and/or to increase the introduction of important new drugs, a review of the local regulatory agencies and the regulations seems worthwhile.

Divergent Paths to Drug Regulation in the United States and the United Kingdom

2002 ◽  
Vol 14 (2) ◽  
pp. 135-169 ◽  
Author(s):  
Stephen Ceccoli
Keyword(s):  
United States ◽  
United Kingdom ◽  
The United States ◽  
Drug Regulation ◽  
New Drugs ◽  
Government Relations ◽  
The United Kingdom ◽  
History Of ◽  
Regulatory Controls ◽  
The Impact

Significant differences in the availability of new medicines in the United States and the United Kingdom became apparent in the 1970s. This article examines the history of drug regulation in the two countries and argues that the divergence was the result of distinctive regulatory approaches that emerged simultaneously throughout the twentieth century. The British approach was based largely on informal, nonstatutory controls, while the American approach relied heavily on centralized regulatory controls. The article argues that the nature of business-government relations has played a significant role in the divergence. The impact of these divergent approaches is apparent in the contemporary regulatory framework, especially with respect to determining the effectiveness of new drugs.

Sign in / Sign up

Export Citation Format

Share Document